Dr. West Discusses Anticipated Future Clinical Trials

Dr. Jack West from the Swedish Cancer Institute Talks About Anticipated Future Clinical Trials

H. Jack West, MD, medical director of the Thoracic Oncology Program at the Swedish Cancer Institute in Seattle, Washington, explains his anticipation to see an overall survival benefit emerge from the PARAMOUNT study examining continuation maintenance with pemetrexed in non-small cell lung cancer. He mentions a strong interest in clinical trials examining next generation studies such as crizotinib in patients that do not have the ALK rearrangement and BRAF targeted therapies which are still in their infancy.